Table 7.

Molecularly targeted agents in the SHIVA study

Targets	Molecular alterations	Molecularly targeted agents
KIT, ABL 1/2, RET	Activating mutation† or amplification*	Imatinib 400 mg qd PO
PI3KCA, AKT1 AKT2, 3, mTOR, RAPTOR, RICTOR PTEN STK11 INPP4B	Activating mutation or amplification Amplification Amplification Homozygous deletion or heterozygous deletion + inactivating mutation or heterozygous deletion + IHC confirmation Homozygous deletion or heterozygous deletion + inactivating mutation Homozygous deletion	Everolimus 10 mg qd PO
BRAF	Activating mutation or amplification Abirterone 1000 mg qd PO	Vemurafenib 960 mg bid PO
PDGFRA/B, FLT3	Activating mutation or amplification	Sorafenib 400 mg bid PO
EGFR	Activating mutation or amplification	Erlotinib 150 mg qd PO
ERBB2/HER2	Activating mutation or amplification	Lapatinib 1000 mg qd PO +  Trastuzumab 8 mg/kg IV followed by 6 mg/kg IV q3w
SRC EPHA2, LCK, YES1	Activating mutation or amplification Amplification	Dasatinib 70 mg bid PO
ER, PR	Protein expression > 10%	Tamoxifen 20 mg qd PO (or letrozole 2–5 mg qd PO if contraindicated)
AR	Protein expression > 10%	Abiraterone 1000 mg qd PO